Cardiometabolic risk reductions in patients with type 2 diabetes mellitus newly treated with a sodium–glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase‐4 inhibitor: A real‐world administrative database study in Japan

AIMS/INTRODUCTION: Sodium–glucose cotransporter 2 inhibitors (SGLT2i) have shown beneficial effects on cardiometabolic risk factors (hemoglobin A1c, body mass index, systolic blood pressure) in patients with type 2 diabetes mellitus. We compared combined cardiometabolic effects of SGLT2i on hemoglob...

Descripción completa

Detalles Bibliográficos
Autores principales: Kashiwagi, Atsunori, Shoji, Shingo, Kosakai, Yoshinori, Koga, Tadashi, Asakawa, Keiko, Rokuda, Mitsuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9951561/
https://www.ncbi.nlm.nih.gov/pubmed/36515129
http://dx.doi.org/10.1111/jdi.13952

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9951561/
https://www.ncbi.nlm.nih.gov/pubmed/36515129
http://dx.doi.org/10.1111/jdi.13952

Ejemplares similares